1. Poovorawan Y, Pyungporn S, Prachayangprecha S,Makkoch J: Global alert to avian influenza virus in-fection: From H5N1 to H7N9. Pathog Glob Health 2013; 107: 217-23
2. WHO Ebola Response Team: Ebola virus disease in West Africa―the first 9 months of the epidemic and forward projections. N Engl J Med 2014; 371: 1481- 95
3. WHO Statement regarding cluster of pneumonia cases in Wuhan, China https://www.who.int/china/news/detail/09-01-2020-who-statement-regardingcluster-of-pneumonia-cases-in-wuhan-china
4. Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, Kozaki K, Nomura N, Egawa H, Minami S, Watanabe Y, Narita H, Shiraki K. 2002. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob. Agents Chemother. 46:977-981.
5. Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, Kozaki K, Nomura N, Egawa H, Shiraki K. 2005. Mechanism of action of T-705 against influenza virus. Antimicrob. Agents Chemother. 49:981-986.
6. Takahashi K, Furuta Y, Fukuda Y, Kuno M, Kamiyama T, Kozaki K, Nomura N, Egawa H, Minami S, Shiraki K. 2003. In vitro and in vivo activities of T-705 and oseltamivir against influenza virus. Antivir. Chem. Chemother. 14:235-241.
7. Sangawa H, Komeno T, Nishikawa H, Yoshida A, Takahashi K, Nomura, Furuta Y. 2013. Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase. Antimicrob Agents Chemother. 57:5202-8.
8. Kiso M, Takahashi K, Sakai-Tagawa Y, Shinya K, Sakabe S, Le QM, Ozawa M, Furuta Y, Kawaoka Y. 2010. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci U S A. 107:882–887.
9. Takahashi K. 2011. Anti influenza viral drugs and pharmacological effect of favipiravir (Japanese). Jon Med Pharm Sci. 66:429-441.
10.Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, Gowen BB, Julander JG, Morrey JD. 2009. T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 82:95- 102.
11.Gowen BB, Wong MH, Jung KH, Sanders AB, Mendenhall M, Bailey KW, Furuta Y, Sidwell RW. 2007. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob. Agents Chemother. 51:3168- 3176.
12.Julander JG, Shafer K, Smee DF, Morrey JD, Furuta Y. 2009. Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob. Agents Chemother. 53:202- 209.
13.Mendenhall M, Russell A, Juelich T, Messina EL, Smee DF, Freiberg AN, Holbrook MR, Furuta Y, de la Torre JC, Nunberg JH, Gowen BB. 2010. T-705 (favipiravir) inhibition of arenavirus replication in cell culture. Antimicrob. Agents Chemother. 55:782-787.
14.Morrey JD, Taro BS, Siddharthan V, Wang H, Smee DF, Christensen AJ, Furuta Y. 2008. Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents. Antiviral Res. 80: 377-379.
15.Oestereich L, Lüdtke A, Wurr S, Rieger T, Muñoz-Fontela C, Günther S. 2014. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res. 105:17–21.
16.Yamada K, Noguchi K, Komeno T, Furuta Y, Nishizono A. 2016. Efficacy of Favipiravir (T-705) in rabies postexposure prophylaxis. J. Infect. Dis. 213:1253– 1261.
17.Furuta Y, Komeno T, Nakamura T. 2017. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci. 93:449- 463.
18.Honda A, Mizumoto K, Ishihama A. 1999. Two separate sequences of PB2 subunit constitute the RNA cap-binding site of influenza virus RNA polymerase. Genes Cells. 4:475-85
19.Asano Y, Ishihama A. 1997. Identification of two nucleotide-binding domains on the PB1 subunit of influenza virus RNA polymerase. J Biochem. 122:627-34.
20.Goldhill DH, Te Velthuis AJW, Fletcher RA, Langat P, Zambon M, Lackenby A, Barclay WS. 2018. The mechanism of resistance to favipiravir in influenza. Proc Natl Acad Sci U S A. 115:11613-18.
21.Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG. 1997. The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res. 25:4876-82.
22.Saitou N, Nei M. 1987. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol. 4:406-25.
23.Kimura M. 1991. The neutral theory of molecular evolution: a review of recent evidence. Jpn J Genet. 66:367-86.
24.Felsenstein J. 1985. Confidence limits on phylogenies: an approach using the bootstrap. Evolution. 39:783-791.
25.Vieth S, Torda AE, Asper M, Schmitz H, Günther S. 2004. Sequence analysis of L RNA of Lassa virus. Virology. 318:153-68
26.Neumann G, Watanabe T, Kawaoka Y. 2000. Plasmid-driven formation of influenza virus-like particles. J Virol. 74:547-51.
27.Jones MH, Learned RM, Tjian R.1988. Analysis of clustered point mutations in the human ribosomal RNA gene promoter by transient expression in vivo. Proc Natl Acad Sci U S A. 85:669-73.
28.Grummt I, Rosenbauer H, Niedermeyer I, Maier U, Ohrlein A.1986. A repeated 18 bp sequence motif in the mouse rDNA spacer mediates binding of a nuclear factor and transcription termination. Cell. 45:837-46.
29.Kinsella E, Martin SG, Grolla A, Czub M, Feldmann H, Flick R. 2004. Sequence determination of the Crimean-Congo hemorrhagic fever virus L segment. Virology. 321:23-8
30.Sakamoto K. 2011. In vitro activities of antiviral agents against foot-and-mouth disease virus RNA-dependent RNA polymerase. Jpn. J. Anim. Hyg. 37:45-9
31.Eriksson B, Helgstrand E, Johansson NG, Larsson A, Misiorny A, Norén JO, Philipson L, Stenberg K, Stening G, Stridh S, Oberg B. 1977. Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob Agents Chemother. 11:946-51.
32.Chu C, Fan S, Li C, Macken C, Kim JH, Hatta M, Neumann G, Kawaoka Y. 2012. Functional analysis of conserved motifs in influenza virus PB1 protein. PLoS One. 7:e36113.
33.Labonté P, Axelrod V, Agarwal A, Aulabaugh A, Amin A, Mak P. 2002. Modulation of hepatitis C virus RNA-dependent RNA polymerase activity by structure-based site-directed mutagenesis. J Biol Chem. 277:38838-46
34.Takashita E, Ejima M, Ogawa R, Fujisaki S, Neumann G, Furuta Y, Kawaoka Y, Tashiro M, Odagiri T. 2016. Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir. Antiviral Res. 132:170-7
35.Goldhill DH, Yan A, Frise R, Zhou J, Shelley J, Gallego Cortés A, Miah S, Akinbami O, Galiano M, Zambon M, Lackenby A, Barclay WS. 2021. Favipiravir-resistant influenza A virus shows potential for transmission. 17:e1008937.
36.Hass M, Lelke M, Busch C, Becker-Ziaja B, Günther S. 2008. Mutational evidence for a structural model of the Lassa virus RNA polymerase domain and identification of two residues, Gly1394 and Asp1395, that are critical for transcription but not replication of the genome. J Virol. 82:10207-17.
37.Iglesias NG, Filomatori CV, Gamarnik AV. 2011. The F1 motif of dengue virus polymerase NS5 is involved in promoter-dependent RNA synthesis. J Virol. 85:5745-56.
38.Delang L, Segura Guerrero N, Tas A, Quérat G, Pastorino B, Froeyen M, Dallmeier K, Jochmans D, Herdewijn P, Bello F, Snijder EJ, de Lamballerie X, Martina B, Neyts J, van Hemert MJ, Leyssen P. 2014. Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral. J Antimicrob Chemother. 69:2770-84.
39.Abdelnabi R, Morais ATS, Leyssen P, Imbert I, Beaucourt S, Blanc H, Froeyen M, Vignuzzi M, Canard B, Neyts J, Delang L. 2017. Understanding the mechanism of the broad-spectrum antiviral activity of Favipiravir (T-705): Key role of the F1 motif of the viral polymerase. J Virol. 91:e00487-17.
40.Tani H, Fukuma A, Fukushi S, Taniguchi S, Yoshikawa T, Iwata-Yoshikawa N, Sato Y, Suzuki T, Nagata N, Hasegawa H, Kawai Y, Uda A, Morikawa S, Shimojima M, Watanabe H, Saijo M. 2016. Efficacy of T-705 (Favipiravir) in the Treatment of Infections with Lethal Severe Fever with Thrombocytopenia Syndrome Virus. mSphere. 1:e00061-15.
41.Tani H, Komeno T, Fukuma A, Fukushi S, Taniguchi S, Shimojima M, Uda A, Morikawa S, Nakajima N, Furuta Y, Saijo M. 2018. Therapeutic effects of favipiravir against severe fever with thrombocytopenia syndrome virus infection in a lethal mouse model: Dose-efficacy studies upon oral administration. PLoS One.13:e0206416.
42.Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. 2020. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30:269-271.
43.Kaptein SJF, Jacobs S, Langendries L, Seldeslachts L, Ter Horst S, Liesenborghs L, Hens B, Vergote V, Heylen E, Barthelemy K, Maas E, De Keyzer C, Bervoets L, Rymenants J, Van Buyten T, Zhang X, Abdelnabi R, Pang J, Williams R, Thibaut HJ, Dallmeier K, Boudewijns R, Wouters J, Augustijns P, Verougstraete N, Cawthorne C, Breuer J, Solas C, Weynand B, Annaert P, Spriet I, Vande Velde G, Neyts J, Rocha-Pereira J, Delang L. 2020.Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity: Proc Natl Acad Sci U S A. 117:26955-26965.
44.Driouich JS, Cochin M, Lingas G, Moureau G, Touret F, Petit PR, Piorkowski G, Barthélémy K, Laprie C, Coutard B, Guedj J, de Lamballerie X, Solas C, Nougairède A. 2021. Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model. Nat Commun. 12:1735.
45.Sheahan TP, Sims AC, Zhou S, Graham RL, Pruijssers AJ, Agostini ML, Leist SR, Schäfer A, Dinnon KH 3rd, Stevens LJ, Chappell JD, Lu X, Hughes TM, George AS, Hill CS, Montgomery SA, Brown AJ, Bluemling GR, Natchus MG, Saindane M, Kolykhalov AA, Painter G, Harcourt J, Tamin A, Thornburg NJ, Swanstrom R, Denison MR, Baric RS. 2020. An orally bioavailable broadspectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 12:eabb5883.
46.Naesens L, Guddat LW, Keough DT, van Kuilenburg AB, Meijer J, Vande Voorde J, Balzarini J. 2013. Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir). Mol Pharmacol. 84:615-29.
47.Karber, G. 1931. Beitrag zur kollecktiven Behandlung pharmakologischer Reihenversuche. Arch. Exptl. Pathol. Pharmakol. 162:480-483.
48.Matsuda S, Kasahara T. 2018. Simultaneous and absolute quantification of nucleoside triphosphates using liquid chromatography-triple quadrupole tandem mass spectrometry. Genes Environ. 40:13.
49.Lim SZ, Chua EW. 2018. Revisiting the Role of Thiopurines in Inflammatory Bowel Disease Through Pharmacogenomics and Use of Novel Methods for Therapeutic Drug Monitoring.Front Pharmacol. 9:1107.
50.Weigel G, Griesmacher A, DeAbreu RA, Wolner E, Mueller MM. 1999. Azathioprine and 6-mercaptopurine alter the nucleotide balance in endothelial cells. Thromb Res. 94:87-94.
51.Smee DF, Hurst BL, Egawa H, Takahashi K, Kadota T, Furuta Y. 2009. Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells. J Antimicrob Chemother. 64:741-6.
52.Soto-Acosta R, Edwards TC, Dreis CD, Krishna VD, Cheeran MC, Qiu L, Xie J, Bonnac LF, Geraghty RJ. 2021. Enhancing the Antiviral Potency of Nucleobases for Potential Broad-Spectrum Antiviral Therapies. Viruses. 13:2508.
53.Yamada K, Noguchi K, Kimitsuki K, Kaimori R, Saito N, Komeno T, Nakajima N, Furuta Y, Nishizono A. 2019. Reevaluation of the efficacy of favipiravir against rabies virus using in vivo imaging analysis. Antiviral Res. 172:104641.
論文の公開元へ
